Get started
Author

Sudarshan Chougule

Early Results from a Phase-2 Study of Varnimcabtagene Autoleucel (IMN-003A), a First-in-India Industry CD19-Directed CAR-T Cell Therapy with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies (IMAGINE Study)
2022 · Sharat Damodar, Sunil Bhat, et al. · Blood · 8
Primary Analysis of Varnimcabtagene Autoleucel (IMN-003A) in Phase 2 Study (IMAGINE), a First-in-India Industry CD19-Directed CAR-T Cell Therapy for Patients with Relapsed Refractory B Cell Malignancies
2023 · Sharat Damodar, Sunil Bhat, et al. · Blood · 4
Comparison of flowcytometry‐based scoring system for the diagnosis of early T precursor‐acute lymphoblastic leukemia
2023 · Deepak Marballi Basavaraju, Shruti Mishra, et al. · Cytometry Part B Clinical Cytometry · 4
PDF
Varnimcabtagene Autoleucel (IMN-003A): Pharmacokinetic Profile with Predominant Naïve and Central Memory Phenotype Demonstrates Sustained In Vivo Persistence and Durable Responses in a First-in-India Industry Phase-2 Study (IMAGINE)
2023 · Sunil Bhat, Sharat Damodar, et al. · Blood · 3
Reinfusion of Varnimcabtagene Autoleucel (IMN-003A) in Patients with Relapsed Refractory B Cell Malignancies Is Feasible with Sustained Responses
2023 · Sharat Damodar, Raja Thirumalairaj, et al. · Blood · 3
Long-Term Safety and Efficacy Outcomes of Varnimcabtagene Autoleucel in Relapsed Refractory B Cell Malignancies: India Phase 2 Imagine Study
2025 · Sharat Damodar, Sunil Bhat, et al. · Transplantation and Cellular Therapy · 2
Factors Associated with Refractoriness or Relapse after Varnimcabtagene Autoleucel (IMN-003A) in Patients with Relapsed Refractory B Cell Malignancies: Phase 2 First-in-India Industry (IMAGINE) Study
2023 · Sharat Damodar, Sunil Bhat, et al. · Blood · 2
PDF
P1409: Phase-2 Study of Varnimcabtagene Autoleucel (imn-003a) First-in-india Industry Cd19-directed Car-t With Fractionated Infusions for Patients With Relapsed Refractory B Cell Malignancies: Imagine Study
2023 · Pankaj Malhotra, Sharat Damodar, et al. · HemaSphere · 2
Response, Peak and Persistence of Varnimcabtagene Autoleucel (IMN-003A), First-in-India Industry CD19-Directed CAR-T Cell Therapy, with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies: Early Results (IMAGINE Study)
2022 · Sunil Bhat, Sharat Damodar, et al. · Blood · 2
Mixed phenotypic acute leukemia: Evolution of classification, molecular basis, and clinical outcomes – a comprehensive review
2026 · Tejaswini Gudibande, Sudarshan Chougule, et al. · African Journal of Medicine and Pharma Research
PDF
Mixed phenotypic acute leukemia, diagnostic challenges and significance of various prognostic markers - A one year follow up a retrospective cohort study
2025 · Tejaswini Gudibande, Sharat Damodar, et al. · IP Journal of diagnostic pathology and oncology/IP journal of diagnostic pathology and oncology/Journal of diagnostic pathology and oncology
PDF
Acute Myeloid Leukemia t (8;21) with Masked Systemic Mastocytosis
2024 · M. B. Deepak, S. Bharath Ram, et al. · Indian Journal of Hematology and Blood Transfusion
PDF
P1364: Pharmacokinetic Profile of Varnimcabtagene Autoleucel (imn-003a), First-in-india Industry Cd19-directed Car-t Cell Therapy for Patients With Relapsed/ Refractory B Cell Malignancies (imagine Study)
2023 · Pankaj Malhotra, Sunil Bhat, et al. · HemaSphere
Varnimcabtagene autoleucel (IMN-003A) in phase-2 first-in-India industry study for relapsed refractory B cell malignancies: B-all pediatric subanalysis (imagine study)
2023 · Sunil Bhat, Raja Thirumalairaj, et al. · Pediatric Hematology Oncology Journal
Works count: 14
Citation count: 30
H-index: 3
I10-index:
Year
Topic
Type